Last updated: March 24, 2026
What are the Patentability Criteria for Biopharmaceuticals in Brazil?
Brazilian patent law adheres closely to the conditions set by the BRPTO (Brazilian Patent Office) and aligns with international standards under the Patent Cooperation Treaty (PCT). Patentability depends on three main criteria:
-
Novelty: The invention must not be disclosed publicly before the filing date. Prior art includes patents, scientific publications, and any public disclosures. For biopharmaceuticals, disclosures in scientific articles or clinical trial data can threaten novelty.
-
Inventive Step: The invention must involve an inventive activity that is not obvious to a person skilled in the pharmaceutical or biotech field. This is assessed by comparing the invention to existing knowledge.
-
Industrial Applicability: The invention must be capable of practical application, such as manufacturing a drug or a method for producing a pharmaceutical compound.
Brazil excludes certain subject matter from patentability:
- Natural products in their natural state.
- Methods of medical treatment or surgery.
- Diagnostic methods and purely mental processes.
Special considerations for biopharmaceuticals: The patent application must specifically claim biotechnological innovations, such as new molecules, production methods, or delivery systems, to avoid classification as mere discoveries or natural phenomena, which are unpatentable.
How Enforceable are Biopharmaceutical Patents in Brazil?
Patent enforcement in Brazil offers legal remedies primarily through courts:
- Patent infringement suits can be filed to prevent unauthorized use.
- Third-party challenges exist via nullity actions, where patents can be invalidated within five years from grant if they do not meet legal standards.
Challenges include:
- Patent term: 20 years from the filing date for application-based patents; data exclusivity is not explicitly granted, which could allow generics post-approval.
- Opposition and nullity proceedings: Brazil allows post-grant opposition, often leading to patent invalidation if invalidity grounds are proved.
- Enforcement delays: Patent lawsuits can take several years to resolve, affecting timely market protection.
Recent developments: The Brazilian judiciary has become more receptive to patent enforcement, but courts require concrete evidence of infringement. Administrative enforcement mechanisms are limited.
What is the Scope of Claims for Biopharmaceutical Patents?
Scope depends on claim drafting precision:
- Product claims: Cover specific molecules, such as a new recombinant protein.
- Process claims: Cover methods of manufacturing or synthesizing biopharmaceuticals.
- Use claims: Cover specific therapeutic indications or methods of use.
- Formulation claims: Cover specific delivery systems or formulations.
Brazilian practice favors narrow claims to avoid invalidation. Broad claims risk being challenged as overly encompassing or covering natural phenomena.
Claim style considerations:
- Claims must be supported by the description.
- Use clear, precise language.
- Avoid overly broad or vague language that can be challenged during examination or enforcement.
Claim amendments: Patent owners can amend claims during prosecution or litigation but must stay within the original disclosure to maintain validity.
Summary of Patent Examination and Claim Policies
| Aspect |
Details |
| Examination authority |
BRPTO (Brazilian Patent Office) |
| Examination process |
Substantive examination required; no automatic examination |
| Patent term |
20 years from filing date |
| Data exclusivity |
Not explicitly granted, limiting market exclusivity |
| Patent scope |
Must be clear, supported by description, and avoid covering natural substances or methods of medical treatment |
Summary of Key Policy and Practice Trends
- Increased scrutiny of biotech and biopharmaceutical applications.
- Greater emphasis on demonstrating inventive step through detailed disclosures.
- Directive trends toward narrowing claims to withstand legal challenges.
- Adoption of international standards for patent search and examination.
Key Takeaways
- Patentability hinges on novelty, inventive step, and industrial applicability, with specific exclusions applicable to natural products and methods.
- Enforcement relies on court actions with possible delays and limited administrative mechanisms.
- Claim scope must be precise, supported, and avoid overreach, particularly in broad compositions or methods.
- Changes in judicial attitudes increasingly favor patent holders, but patent drafting remains critical.
FAQs
1. Can naturally occurring substances be patented in Brazil?
Natural substances in their isolated form may be patentable if they involve a new application or specific manufacturing process. Pure discoveries of natural phenomena are excluded from patentability.
2. Is there data exclusivity for biopharmaceuticals in Brazil?
No explicit data exclusivity exists. Biopharmaceutical data from clinical trials can be used in patent disputes, but market exclusivity depends largely on patent protections and regulatory approval.
3. What is the typical duration for patent examination in Brazil?
The timeline varies; substantive examination can take 3-5 years post-filing, with delays affecting patent grant timing.
4. How can patent claims be challenged or invalidated?
Claims can be challenged through nullity actions within five years of grant, or during opposition proceedings post-grant, based on lack of novelty, inventive step, or statutory exclusions.
5. Are methods of medical treatment patentable in Brazil?
No. Methods of medical or surgical treatment are explicitly excluded from patentability under Brazilian law.
References
[1] Brazilian Patent Law, Law No. 9,279/1996.
[2] World Intellectual Property Organization. (2021). Patent law guide.
[3] Brazilian Patent Office. (2022). Guidelines for patent examination.
[4] World Trade Organization. (2022). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
[5] Alves, G., & de Souza, T. (2020). Patent strategies in the biotech sector: Focus on Brazil. Journal of Intellectual Property Law.
